Celgene (CELG) - 28 Year Stock Price History

Historical daily stock prices for Celgene since 1990 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Celgene (CELG) as of April 20, 2018 is 88.95.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $66.906B $13.003B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.